Tuesday May 12, 2020 0 comments
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology-based therapies for prevalent inflammatory conditions, today announced a manuscript accepted for publication in The Journal of Patient Safety in Surgery that shows Ampion treatment could improve clinical outcomes for COVID-19 patients.
The manuscript titled, "The novel immunomodulatory biologic LMWF5A (Ampion) for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis", provides a detailed description of the biochemical and immunological phenomena collectively termed the "cytokine storm" encountered in COVID-19 patients and evaluates the potential benefit of Ampion treatment for these patients.
A link to the publication will be provided on the company's website once available.
Ampio has submitted an Investigational New Drug ("IND") Application to the FDA for the use of nebulized Ampion to treat COVID-19 patients with acute respiratory distress syndrome ("ARDS") and is engaged in active discussions with the CBER division of the FDA with the goal to obtain permission to initiate a U.S. clinical trial.